Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or prophylaxis in clinical practice. The present study ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tingting, Li, Xuening, Chen, Yanwei, Du, Jie, Chen, Xiaodong, Wang, Dalong, Wang, Liyan, Zhao, Shan, Wang, Changyuan, Meng, Qiang, Sun, Huijun, Liu, Kexin, Wu, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441481/
https://www.ncbi.nlm.nih.gov/pubmed/36071847
http://dx.doi.org/10.3389/fphar.2022.914842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441481/
https://www.ncbi.nlm.nih.gov/pubmed/36071847
http://dx.doi.org/10.3389/fphar.2022.914842

Ejemplares similares